Who are Comparator: montelukast/loratadine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Montelukast mixed with Loratadine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparator-montelukast-loratadine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Comparator: montelukast/loratadine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparator: montelukast/loratadine (Comparator: montelukast/loratadine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukotriene receptor antagonist / Antihistamine combination. Area: Immunology / Allergy / Respiratory.

phase 3 Leukotriene receptor antagonist / Antihistamine combination Cysteinyl leukotriene receptor (CysLT1) and H1 histamine receptor Immunology / Allergy / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: montelukast/loratadine (Comparator: montelukast/loratadine) — Organon and Co. This is a fixed-dose combination of montelukast (a cysteinyl leukotriene receptor antagonist) and loratadine (a selective H1-receptor antagonist) that reduces airway inflammation and blocks allergic mediators.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: montelukast/loratadine TARGET	Comparator: montelukast/loratadine	Organon and Co	phase 3	Leukotriene receptor antagonist / Antihistamine combination	Cysteinyl leukotriene receptor (CysLT1) and H1 histamine receptor
Montelukast mixed with Loratadine	Montelukast mixed with Loratadine	Innovacion y Desarrollo de Estrategias en Salud	phase 3	Leukotriene receptor antagonist / Antihistamine combination	CysLT1 receptor (montelukast) and H1 receptor (loratadine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukotriene receptor antagonist / Antihistamine combination class)

Innovacion y Desarrollo de Estrategias en Salud · 1 drug in this class
Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: montelukast/loratadine — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-montelukast-loratadine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab